Ridgeback Biotherapeutics LP announces the approval of Ebanga for Ebola.

Ridgeback Biotherapeutics LP a biotechnology company experienced in antiviral drug development, announced that the FDA approved Ebanga (ansuvimab-zykl) for the treatment of Ebola. Ebanga is now approved for treatment of infection caused by Zaire ebolavirus in adult and pediatric patients (including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection). Ebanga is the only FDA approved, single injection Ebola treatment which is available in a lyophilized form. Ridgeback will continue to make Ebanga available to patients who need it. In 2020, Ridgeback initiated a compassionate use protocol for Ebola patients during the DRC’s 11th Ebola outbreak in Équateur Province. Ebanga was provided to all PCR-positive Ebola patients under this protocol.